PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for retinal and central nervous system diseases. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa Boerse Stuttgart, saham PYC Therapeutics Limited diperdagangkan dengan simbol PH7.STU.
Kapan tanggal laporan keuangan berikutnya dari PYC Therapeutics Limited?▼
PYC Therapeutics Limited akan merilis laporan keuangan berikutnya pada Agustus 27, 2026.
Bagaimana laporan keuangan PYC Therapeutics Limited pada kuartal lalu?▼
Laporan keuangan PH7.STU untuk kuartal terakhir adalah -0,02 EUR per saham, sedangkan perkiraannya -0,04 EUR, menghasilkan kejutan sebesar +40,24%. Perkiraan laba untuk kuartal berikutnya adalah N/A EUR per saham.
PYC Therapeutics Limited berada di sektor apa?▼
PYC Therapeutics Limited beroperasi di sektor Kesehatan & Kebugaran.